Having trouble accessing articles? Reset your cache.

Reviewers back Pradaxa in briefing docs

FDA reviewers recommended approval of Pradaxa dabigatran from Boehringer Ingelheim GmbH (Ingelheim, Germany) in briefing documents posted ahead of Monday's advisory

Read the full 216 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE